Spots Global Cancer Trial Database for enasidenib
Every month we try and update this database with for enasidenib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | NCT05010772 | Acute Myeloid L... | Decitabine and ... Enasidenib Gilteritinib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation | NCT04203316 | Recurrent Acute... Refractory Acut... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Enasidenib Enasidenib Mesy... | 24 Months - 21 Years | Children's Oncology Group | |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation | NCT02577406 | Leukemia, Myelo... Isocitrate Dehy... | AG-221 BSC Azacitidine Low-dose cytara... Intermediate-do... | 60 Years - | Celgene | |
| A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance | NCT05102370 | Clonal Cytopeni... CCUS Clonal Cyt... | Enasidenib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | NCT03383575 | Acute Myeloid L... Blasts 20-30 Pe... Chronic Myelomo... IDH2 Gene Mutat... Myelodysplastic... Recurrent High ... Refractory High... | Azacitidine Enasidenib Quality-of-Life... | 12 Years - | M.D. Anderson Cancer Center | |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation | NCT04203316 | Recurrent Acute... Refractory Acut... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Enasidenib Enasidenib Mesy... | 24 Months - 21 Years | Children's Oncology Group | |
| Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NCT04774393 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Decitabine and ... Enasidenib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | NCT05010772 | Acute Myeloid L... | Decitabine and ... Enasidenib Gilteritinib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | NCT06176989 | Metastatic Chon... Locally Advance... Metastatic Sino... Locally Advance... Metastatic Larg... Locally Advance... Metastatic Olfa... Locally Advance... Metastatic Sino... Locally Advance... | Enasidenib | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | NCT05010772 | Acute Myeloid L... | Decitabine and ... Enasidenib Gilteritinib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance | NCT05102370 | Clonal Cytopeni... CCUS Clonal Cyt... | Enasidenib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia | NCT04075747 | Acute Myeloid L... | CPX-351 Venetoclax Midostaurin Enasidenib | 18 Years - 75 Years | Jazz Pharmaceuticals | |
| Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | NCT06176989 | Metastatic Chon... Locally Advance... Metastatic Sino... Locally Advance... Metastatic Larg... Locally Advance... Metastatic Olfa... Locally Advance... Metastatic Sino... Locally Advance... | Enasidenib | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients | NCT03720366 | Leukemia, Myelo... | enasidenib Arm 1 probes Arm 2 Probes Arm 3 probes | 18 Years - | Celgene | |
| Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | NCT04092179 | Acute Myeloid L... Relapsed Cancer Refractory Canc... IDH2 Gene Mutat... | Enasidenib Venetoclax | 18 Years - | University Health Network, Toronto |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
